Sanofi collaborates on AI-driven medication development with Formation Bio and OpenAI

French pharmaceutical giant Sanofi (SASY.PA) announced on Tuesday its collaboration with Formation Bio and OpenAI, an artificial intelligence company, to enhance its drug research efforts using AI.

In a statement, Sanofi mentioned that Formation Bio will provide additional engineering resources, while the partnership with OpenAI will grant access to proprietary data to develop AI models for its biopharma initiatives.

Major pharmaceutical companies are increasingly leveraging artificial intelligence to identify clinical trial participants more efficiently and reduce the number of subjects needed for drug testing, potentially accelerating drug development and saving millions of dollars.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Sign Up for CXO Digital Pulse Newsletters

Sign Up for CXO Digital Pulse Newsletters to Download the Research Report

Sign Up for CXO Digital Pulse Newsletters to Download the Coffee Table Book

Sign Up for CXO Digital Pulse Newsletters to Download the Vision 2023 Research Report

Download 8 Key Insights for Manufacturing for 2023 Report

Sign Up for CISO Handbook 2023

Download India’s Cybersecurity Outlook 2023 Report

Unlock Exclusive Insights: Access the article